Abstract
Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Keywords: Coronavirus, main protease, drug design
Current Pharmaceutical Design
Title: Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses
Volume: 12 Issue: 35
Author(s): Haitao Yang, Mark Bartlam and Zihe Rao
Affiliation:
Keywords: Coronavirus, main protease, drug design
Abstract: Coronaviruses (CoVs), a genus containing about 26 known species to date, cause highly prevalent diseases and are often severe or fatal in humans and animals. In 2003, a previously unknown coronavirus was identified to be the etiological agent of a global outbreak of a form of life-threatening pneumonia called severe acute respiratory syndrome (SARS). No efficacious therapy is currently available, and vaccines and drugs are under development to prevent SARSCoV infection in many countries. The CoV main protease (Mpro), which plays a pivotal role in viral gene expression and replication through a highly complex cascade involving the proteolytic processing of replicase polyproteins, is an attractive target for drug design. This review summarizes the recent advances in biological and structural studies, together with development of inhibitors targeting CoV Mpros. It is expected that inhibitors targeting CoV Mpros could be developed into wide-spectrum antiviral drugs against existing and possible future emerging CoV-associated diseases.
Export Options
About this article
Cite this article as:
Yang Haitao, Bartlam Mark and Rao Zihe, Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses, Current Pharmaceutical Design 2006; 12 (35) . https://dx.doi.org/10.2174/138161206779010369
DOI https://dx.doi.org/10.2174/138161206779010369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Peptidic HIV Protease Inhibitors
Current Topics in Medicinal Chemistry Biodiversity as a Source of Bioactive Compounds Against Snakebites
Current Medicinal Chemistry Chitin Synthase As an Antifungal Target: Recent Advances
Current Medicinal Chemistry - Anti-Infective Agents Design, Synthesis and In Vitro Antimalarial Evaluation of New Quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory Bowel Disease (IBD)
Current Pharmaceutical Design Respiratory Stem Cells and Progenitors: Overview, Derivation, Differentiation, Carcinogenesis, Regeneration and Therapeutic Application
Current Stem Cell Research & Therapy Prolyl Oligopeptidase Structure and Dynamics
CNS & Neurological Disorders - Drug Targets In Silico Studies in ADME/Tox: Caveat Emptor
Current Computer-Aided Drug Design Preclinical Models of Graves’ Disease and Associated Secondary Complications
Current Pharmaceutical Design Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1
Current Medicinal Chemistry Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early Intervention
Current Neuropharmacology Integrated Ligand Based Pharmacophore Model Derived from Diverse FAAH Covalent Ligand Classes
Current Computer-Aided Drug Design Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Bioactive Secondary Metabolites from a Thai Collection of Soil and Marine-Derived Fungi of the Genera Neosartorya and Aspergillus
Current Drug Delivery Triamcinolone as a Potential Inhibitor of SARS-CoV-2 Main Protease and Cytokine Storm: An <i>In silico</i> Study
Letters in Drug Design & Discovery Heterogeneous Catalysis in the Meerwein-Ponndorf-Verley Reduction of Carbonyl Compounds
Current Organic Chemistry Novel Urea/Thiourea Derivatives of Quinazolin-4(3H)-one: Design, Synthesis, Antimicrobial and Anti-TB Study
Letters in Drug Design & Discovery A Synthetic Approach and Antimicrobial Evaluation of Annulated Pyrimidine and Triazine Derivatives
Current Organic Chemistry Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets